GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
In breast cancer patients, tumor heterogeneity is associated with prognosis and therapeutic response; however, the epigenetic diversity that exists in primary tumors remains unknown. Using a single-cell sequencing assay for transposase-accessible chromatin (scATAC-seq), we obtained the chromatin accessibility profiles of 12,452 cells from 16 breast cancer patients including 11 luminal, 1 luminal-HER2, 1 HER2+, and 3 triple-negative subtypes. Via this profiling process, tumors were classified into cancer cells and the tumor microenvironment, highlighting the heterogeneity of disease-related pathways including estrogen receptor (ER) signaling. Furthermore, the coexistence of cancer cell clusters with different ER binding motif enrichments was identified in a single ER+ tumor. In a cluster with reduced ER motif enrichment, we identified GRHL2, a transcription factor, as the most enriched motif, and it cooperated with FOXA1 to initiate endocrine resistance. Coaccessibility analysis revealed that GRHL2 binding elements potentially regulate genes associated with endocrine resistance, metastasis, and poor prognosis in patients that received hormonal therapy. Overall, our study suggests that epigenetic heterogeneity could lead to endocrine resistance and poor prognosis in breast cancer patients and it offers a large-scale resource for further cancer research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Self-citationComprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
GREAT improves functional interpretation of cis-regulatory regions
McLean, C. Y., Bristor, D., Hiller, M., Clarke, S. L., Schaar, B. T., Lowe, C. B., Wenger, A. M., & Bejerano, G. (2010) · Nature Biotechnology · doi:10.1038/nbt.1630 · Cited by 4,502
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
Colaprico, A., Silva, T. C., Olsen, C., Garofano, L., Cava, C., Garolini, D., Sabedot, T. S., Malta, T. M., Pagnotta, S. M., Castiglioni, I., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1507 · Cited by 4,183
Cited by
Epigenetic regulation during cancer transitions across 11 tumour types
Terekhanova, N. V., Karpova, A., Liang, W.-W., Strzalkowski, A., Chen, S., Li, Y., Southard-Smith, A. N., Iglesia, M. D., Wendl, M. C., Jayasinghe, R. G., et al. (2023) · Nature · doi:10.1038/s41586-023-06682-5 · Cited by 207
Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity
Hu, Y., Shen, F., Yang, X., Han, T., Long, Z., Wen, J., Huang, J., Shen, J., & Guo, Q. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01574-x · Cited by 108
“Another study, by scATAC-seq of 12 breast cancer patients, found that the transcription factor GRHL2 cooperates with FOXA1 to initiate endocrine resistance and that epigenetic heterogeneity may contribute to endocrine resistance in breast cancer patients [70].”
BackgroundEpigenomic heterogeneity as a source of tumour evolution
Laisné, M., Lupien, M., & Vallot, C. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00757-9 · Cited by 113
Subbalakshmi, A. R., Sahoo, S., Manjunatha, P., Goyal, S., Kasiviswanathan, V. A., Mahesh, Y., Ramu, S., McMullen, I., Somarelli, J. A., & Jolly, M. K. (2023) · Journal of Biological Engineering · doi:10.1186/s13036-023-00333-z · Cited by 45
“GRHL2 has also been reported to be lineage-specific driver of reprogrammed estrogen signaling and an enabler of endocrine resistance in ER+ breast cancer (Cocce et al., 2019; Kumegawa et al., 2022).”
BackgroundFang, K., Ohihoin, A. G., Liu, T., Choppavarapu, L., Nosirov, B., Wang, Q., Yu, X., Kamaraju, S., Leone, G. W., & Jin, V. X. (2024) · Genome Medicine · doi:10.1186/s13073-024-01407-3 · Cited by 38
Metadata
- Authors
- Kumegawa, K., Takahashi, Y., Saeki, S., Yang, L., Nakadai, T., Osako, T., Mori, S., Noda, T., Ohno, S., Ueno, T., & Maruyama, R.
- Affiliations
- Japanese Foundation For Cancer Research (JP)
- The Cancer Institute Hospital (JP)
- Corresponding author
- Maruyama, Reo
- ORCID
- Venue
- npj Breast Cancer
- Published
- 2022-06-08
- Volume
- 8
- Issue
- 1
- Pages
- 70-70
- ISSN
- 2374-4677 (ISSN-L)
- PMC
- PMC9177858
- OpenAlex
- W4281754371
- Cited by
- 45
- References
- 46
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 19 · 2023: 6
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Breast Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Agency for Medical Research and Development (21fk0210054h0003, JP21fk0210092)
- Japan Society for the Promotion of Science (22K07161, 17K18336, 17K10568, 21H02793, 21K06898, 20K07708)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- GRHL2, luminal breast cancer, intratumoral heterogeneity, cis-regulatory elements, chromatin accessibility, estrogen receptor signaling, endocrine therapy resistance, FOXA1, tumor microenvironment, single-cell ATAC-seq, HER2-positive breast cancer, triple-negative breast cancer, metastasis, prognosis, hormone therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. https://app.cochat.ai/papers/10.1038/s41523-022-00438-6
- The paper
- Kumegawa, K., Takahashi, Y., Saeki, S., Yang, L., Nakadai, T., Osako, T., Mori, S., Noda, T., Ohno, S., Ueno, T., & Maruyama, R. (2022). GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. npj Breast Cancer. https://doi.org/10.1038/s41523-022-00438-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.